Table II.
Characteristics | ESBL+ KP (n=34) | ESBL- KP (n=41) | P-value | OR (95% CI) |
---|---|---|---|---|
Demographics | ||||
Age, median (IQR) | 70.1 | 62.6 | 0.0365 | |
Male sex | 22 (64.7%) | 15 (36.5%) | 0.0080 | 3.177 (1.231-8.200) |
Previous conditions | ||||
Hospitalizations in the past 6 months | 20 (58.8%) | 5 (12.1%) | <0.0001 | 10.285 (3.23-32.752) |
Antibiotic treatment in the last 30 days | 9 (26.4%) | 4 (9.7%) | 0.0340 | 3.330 (0.923-12006) |
Underlying conditions | ||||
Chronic kidney disease | 8 (23.5%) | 3 (7.31%) | 0.0296 | 3.897 (0.944-16.085) |
Recurrent UTIs | 12 (35.2%) | 7 (17.0%) | 0.0404 | 2.694 (0.903-7.765) |
Cardiovascular diseases | 24 (70.5%) | 20 (48.7%) | 0.0309 | 2.520 (0.966-6.573) |
Diabetes mellitus | 10 (29.4%) | 13 (31.7%) | 0.4180 | 0.897 (0.334-2.411) |
Chronic liver disease | 6 (17.6%) | 13 (31.7%) | 0.0880 | 0.461 (0.153-1.386) |
Malignancy | 11 (32.3%) | 5 (12.1%) | 0.0203 | 3.443 (1.058-11.201) |
Cerebrovascular disease | 11 (32.3%) | 9 (21.9%) | 0.1630 | 1.700 (0.606-4.768) |
Obesity | 7 (20.5%) | 9 (21.9%) | 0.4470 | 0.921 (0.303-2.804) |
Charlson comorbidity index, median (IQR) | 5.7 | 3.5 | 0.0005 | |
Urinary catheterization | 15 (44.1%) | 5 (12.1%) | 0.0011 | 5.684 (1.791-18.036) |
Laboratory findings | ||||
Hemoglobin <11.7 g/dl | 16 (47.0%) | 11 (26.8%) | 0.0385 | 2.424 (0.923-6.361) |
White blood cells >10,000/mm3 | 19 (55.8%) | 19 (46.3%) | 0.2113 | 1.466 (0.588-3.657) |
Erythrocyte sedimentation rate >12 mm/h | 24 (32.0%) | 36 (48.0%) | 0.0372 | 0.333 (0.101-1.097) |
Treatment | ||||
Inappropriate empirical therapy | 18 (52.9%) | 19 (46.3%) | 0.3334 | 1.226 (0.496-3.025) |
Targeted therapy | 17 (47.0%) | 22 (53.6%) |
All data are expressed as n (%). UTI, urinary tract infections; KB, Klebsiella pneumoniae; ESBL, extended-spectrum β-lactamase; ESBL+ KP, ESBL-producing K. pneumoniae; ESBL- KP, non-ESBL producing KP. IQR, interquartile range; OR, odds ratio; CI, confidence interval. Significant P-values are presented in bold print.